Rhizoxin

Drug Profile

Rhizoxin

Alternative Names: FR 900216; NSC 332598; WF 1360

Latest Information Update: 30 Jul 2007

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Class
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Head and neck cancer; Non-small cell lung cancer

Most Recent Events

  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 08 Jan 2001 Phase-II clinical trials for Non-small cell lung cancer in United Kingdom (IV)
  • 08 Jan 2001 Phase-II clinical trials for Non-small cell lung cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top